drugset / Trial / NCT03599726

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

NCT03599726

RandomizedCrossoverQuadruple-blindBasic science

Summary

Safe and independent mobility at home and in the community requires control of walking while accomplishing other functional tasks. A hallmark of healthy control of walking is automaticity, defined as the ability of the nervous system to successfully coordinate movement with minimal use of attention-demanding executive resources \[1\]. Recent evidence indicates that walking disorders are often characterized by a shift in the locomotor control strategy from healthy automaticity to compensatory executive control. This shift is potentially detrimental to walking performance as an executive control strategy is not optimized for locomotor control and it places excessive demands on a limited pool of cognitive reserve. Here, the investigators hypothesize that walking automaticity, as measured by the prefrontal cortex activity while walking, will be improved by donepezil (a cholinesterase inhibitor).

Timeline

Start
2018-07-30
Primary completion
2019-05-30
Completion
2019-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg Oral

Indications